Hidden gut bacteria may be key to a healthy microbiota

Uncultured gut bacteria, particularly one group called CAG-170, are key contributors to a healthy microbiota. 

From tradition to innovation: the new age of fermented cosmetic ingredients

Building the future with advanced biotechnology.

Dietary fiber and gastric cancer: pooled international data support a dose-dependent protective effect

Giulia Collattuzzo, University of Bologna, presents study findings showing an independent protective association between dietary fiber and gastric cancer risk, with consistent effects across sex, tumor location, and histological subtype.

The Fastest Lab on Earth

Why Formula 1 will build the future of personalised medicine before medicine does.

Vitafoods Europe 2026: from market expansion to innovation in action

The report by MicrobiomePost distills key trends from Vitafoods Europe 2026.

Region-specific infant gut bacteria may pave the way for tailored probiotics

Bifidobacterium longum and B. infantis are distinct species with strains adapted to local diets, highlighting the importance of developing geographically tailored infant probiotics.

Gut protein blocks harmful bacteria and protects intestinal health

HMGB1 is a key protein that blocks bacterial adhesion and virulence, protecting intestinal cells and helping to maintain a healthy microbiota.

IBS Days 2026: Bologna to host the European launch of the new Rome V criteria

The fifth edition of IBS Days, a congress entirely dedicated to Irritable Bowel Syndrome, will take place in Bologna, Italy, from June 15 to 17, 2026.

Postbiotics as a new frontier in healthcare: from gut barrier function to cancer immunotherapy

Giuseppe Penna, from Humanitas University (Italy), presents the development of a novel postbiotic obtained from a single bacterial strain through an innovative fermentation process.

Targeting the gut microbiota in IBD: from diet and probiotics to fecal microbiota transplantation

Giovanni Marasco, University of Bologna, discusses the growing evidence that links gut microbiota dysbiosis to the pathophysiology, clinical prognosis, disease progression, and treatment response of patients with IBD.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.